Prescribing patterns in patients with chronic liver and kidney disease in a tertiary care hospital
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240325Keywords:
Liver disease, ALD, CLDAbstract
Background: Liver diseases are major cause of mortality and morbidity worldwide. It is the 12th leading cause of death liver diseases can be classified as acute if the onset of symptom does not exceed six months or chronic if symptoms persist beyond this period. According to the recently available World Health Organization. The aim of study is to facilitate rational use of medicines.
Methods: This study is a prospective, observational, single center study which include patients aged ≥18 years, diagnosis of liver diseases with or without co-morbidities and is conducted at out-patient of Medicine department, Rajindra Medical College and Hospital, Patiala.
Results: In this study, total of 97 prescriptions of patients with liver disease were analyzed. Out of 97 patients, the majority of patients were male. In ALD, males were 32 (78%) whereas female were 9 (22%) while in CLD males were 47 (84%) and females were 9 (16%).While observing the LFT profile of patients with ALD common tests were observed which includes total bilirubin (1.82±2.42), SGOT (96.81±117.49) and SGPT (94.78±142.94) and in patients with CLD common tests were observed which includes total bilirubin (2.50±3.63), SGOT (67.50±43.04), SGPT (47.10±33.12), blood urea (46.92±24.14) and alkaline phosphatase (147.02±63.14).
Conclusions: The study interprets the prescribing pattern of drugs used in patients with ALD and CLD and observed that vitamins and minerals and antibiotics were the most prescribed in order to avoid further complications followed by hepatoprotective agents, antiulcer drugs, antihypertensives and laxatives.
References
Hong M, Li S, Tan H, Wang N, Tsao SW, Feng Y. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects. Int J Mol Sci. 2015;16(12):28705-45.
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-107.
Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-81.
Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253-60.
Meena VK, Atray M, Agrawal A. Evaluation of Drug Utilization Pattern In Indoor Patients Of Medicine Department At Tertiary Care Teaching Hospital In Southern Rajasthan. IJPSR. 2016;7(9):3835-40.
Hambley BC, Diamond A, Connie S, Partovi S, Smith T, LoPresti C. Effect of vitamin K on coagulopathy of liver disease: a single center retrospective review. Blood. 2016;128(22):2583.
Machowska A, Lundborg CS. Drivers of Irrational Use of Antibiotics in Europe. Int J Environ Res Public Health. 2019;16(1):27.
Vijayan M, Anisha KA, Selina AS, Roshni PR. Clinical Profile and Prescribing Pattern of Cirrhosis in a Tertiary Care Hospital. Indian J Pharm Pract. 2014;7(3):69.
Liver diseases in Europe. The Lancet. 2021. Available at: https://www.thelancet.com/info graphics-do/liver-disease-europe. Accessed on 12 August 2023.
Gawande A, Gupta GK, Gupta A, Wanjari SJ, Goel V, Rathore V, et al. Acute-on-Chronic Liver Failure: Etiology of Chronic and Acute Precipitating Factors and Their Effect on Mortality. Dig Dis. 1991;9:189-93.
Hong YM, Yoon KT, Heo J, Woo HY, Lim W, An DS, Han JH, Cho M. The prescription pattern of acetaminophen and non-steroidal anti-inflammatory drugs in patients with liver cirrhosis. J Korean Med Sci. 2016;31(10):1604-10.
Hong M, Li S, Tan H, Wang N, Tsao SW, Feng Y. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects. Int J Mol Sci. 2015;16(12):28705-45.
